Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

Keyphrases

• Heart Failure 100%
• Clinical Status 100%
• Tolvaptan 100%
• Everest 100%
• Vasopressin Antagonists 100%
• Short-term Clinical Effect 100%
• Placebo 30%
• Dyspnea 20%
• Serious Adverse Events 20%
• Congestion 20%
• Between-group 20%
• Hospitalization 10%
• Prospective Randomized Trial 10%
• Renal Failure 10%
• Hypotension 10%
• North America 10%
• Placebo-controlled Trial 10%
• South America 10%
• Diuretics 10%
• Short-term Effects 10%
• Edema 10%
• Event Frequency 10%
• Nonapeptides 10%
• Vasopressin V2 Receptor Antagonist 10%
• Visual Analog Scale 10%
• Failure Cause 10%
• Heart Failure Outcomes 10%
• Vasopressin Antagonism 10%
• Peripheral Edema 10%
• Body Weight Reduction 10%
• South Europe 10%
• Rank Sum 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 100%
• Tolvaptan 100%
• Vasopressin Antagonist 100%
• Placebo 40%
• Adverse Event 20%
• Dyspnea 20%
• Hypotension 10%
• Kidney Failure 10%
• Physical Disease by Body Function 10%
• Diuretic Agent 10%
• Vasopressin V2 Receptor 10%
• Edema 10%
• Receptor Antagonist 10%
• Peripheral Edema 10%
• Vasopressin 10%